Project Grant F32AI202844
Award Date 7/27/26
Completion Date 8/31/29
Dollars Obligated $160K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Denver, CO 80210, USA
Similar Awards
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the Regents of the University of Colorado-Denver a $2,637,034 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective August 8, 2025, with completion targeted for July 31, 2029. This award funds biomedical research investigating the molecular mechanisms by which the actin-binding protein synaptopodin facilitates intracellular bacterial spread,...
- The National Institute of Allergy and Infectious Diseases awarded The Regents of the University of Colorado $221,875 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to establish mechanisms by which the AcrAB-TolC resistance-nodulation-division (RND) efflux pump contributes to bacterial virulence in Enterobacteriaceae. The research will determine whether AcrAB-TolC is required for infection to enable physiological responses to nitrosative stress and...
- The National Institute of Allergy and Infectious Diseases awarded Colorado State University $423,500 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate bacteriophage interactions with nontuberculous mycobacteria in mammalian cell intracellular environments. The research addresses the therapeutic use of bacteriophages—naturally occurring viruses that infect and kill bacteria—as an alternative treatment for drug-resistant nontuberculous...
- The National Institute of Allergy and Infectious Diseases awarded The Regents Of The University Of Colorado (doing business as University Of Colorado-Denver) $153,680 on November 1, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The research investigates the role of type 1 interferon signaling in promoting antigen archiving and vaccine stability within lymphatic endothelial cells. Lymphatic endothelial cells serve as the first point of contact for antigens and...
- The National Institute of Allergy and Infectious Diseases awarded Northwestern University $159,140 on August 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct molecular epidemiology research on New Delhi metallo-B-lactamase-producing Enterobacterales (NDM-E) infections. The research integrates genotype, phenotype, and patient-level outcomes to develop allele-specific therapeutic guidance for NDM-E treatment. Aim 1 defines the genetic epidemiology of...
- The National Institute of Allergy and Infectious Diseases awarded $766,730 to the University of Colorado-Denver on February 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate bacteriocins produced by Staphylococcus hominis skin commensals and their protective mechanisms against skin pathogens. The research focuses on identifying and characterizing diverse bacteriocins produced by S. hominis strains isolated from human skin that inhibit pathogenic S....
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded $571,412 to the University of Maryland, College Park on June 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into the regulation of bacterial physiology and infections through linear diribonucleotides and RNA degradation. The project will characterize how diribonucleases and triribonucleases bind their respective...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded University of Colorado-Denver $2.73 million under the Allergy and Infectious Diseases Research program (CFDA 93.855) for a four-year Project Grant effective September 4, 2025, through August 31, 2029. This award supports investigator-initiated biomedical research examining the mechanisms by which phage-salmonella interactions function during oxidative stress conditions. The research addresses...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Colorado (University of Colorado-Denver) $429,000 under CFDA 93.855 (Allergy and Infectious Diseases Research) on June 8, 2026, to engineer enterococcal bacteriophages as immunomodulatory agents for inflammatory bowel disease. The project will engineer bacteriophages to perform dual functions: deplete pathogenic enterococci from the intestine while simultaneously delivering heterologous...
- The National Institute of Allergy and Infectious Diseases awarded Emory University $161,244 on April 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct experimental evolution assays elucidating evolutionary trajectories to antibiotic resistance in Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli, and how the immune system modifies these trajectories. The research uses in vivo adaptive laboratory evolution experiments in Galleria...